Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03298087
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- NCT03298087 ↗
- Completed
- VA Office of Research and Development
- Focused
We haven't built an HCP commentary report on NCT03298087 (apalutamide plus abiraterone plus leuprolide in newly diagnosed oligometastatic prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03298087 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Newly Diagnosed Oligometastatic Prostate Cancer
- Interventions
- radical prostatectomy; stereotactic body radiotherapy; Leuprolide; apalutamide; abiraterone
- Arms
- Experimental Arm · Experimental
- Enrollment
- 28
- Primary outcomes
- Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation)
- Sponsor
- VA Office of Research and Development
- Start
- Jul 1, 2018
- Primary completion
- Mar 31, 2024
- Results posted
- Yes
- Registry record
- NCT03298087 · updated Aug 1, 2025
Publications
linked from the registry- Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5. PubMed 30935383